# An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia

> **NCT01009047** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 228 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone extended release (ER)
- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT01009047
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2013-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009047, "An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01009047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*